GEN-MEDROXY TABLET 10MG

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

MEDROXYPROGESTERONE ACETATE

から入手可能:

GENPHARM ULC

ATCコード:

G03DA02

INN（国際名）:

MEDROXYPROGESTERONE

投薬量:

10MG

医薬品形態:

TABLET

構図:

MEDROXYPROGESTERONE ACETATE 10MG

投与経路:

ORAL

パッケージ内のユニット:

100/500

処方タイプ:

Prescription

治療領域:

PROGESTINS

製品概要:

Active ingredient group (AIG) number: 0106339006; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2010-08-04

製品の特徴

PRODUCT MONOGRAPH
PR GEN-MEDROXY
MEDROXYPROGESTERONE ACETATE TABLETS USP
2.5 MG, 5 MG AND 10 MG
PROGESTAGEN-PROGESTATIONAL STEROID
GENPHARM INC. DATE OF PREPARATION: NOVEMBER 08, 2003
37 ADVANCE ROAD DATE OF REVISION: APRIL 19, 2004
ETOBICOKE, ONTARIO
M8Z 2S6 CONTROL NUMBER: 084817
1
WARNING
As the Women’s Health Initiative (WHI) study results indicated
increased risk of myocardial
infarction (MI), stroke, invasive breast cancer, pulmonary emboli and
deep venous thrombosis
in postmenopausal women receiving treatment with combined conjugated
equine estrogens and
medroxyprogesterone acetate compared to those receiving placebo
tablets, the following
should be highly considered:
C
Estrogen with or without progestins
SHOULD NOT
be prescribed for primary or secondary
prevention of cardiovascular diseases.
C
Estrogens with or without progestins should be prescribed at
THE LOWEST EFFECTIVE DOSE
for the approved indication.
C
Estrogen with or without progestins should be prescribed for
THE SHORTEST PERIOD
possible for the recognized indication
.
PRODUCT MONOGRAPH
PR GEN-MEDROXY
(MEDROXYPROGESTERONE ACETATE TABLETS, USP) 2.5 MG, 5 MG AND 10 MG
PHARMACOLOGIC CLASSIFICATION
PROGESTAGEN-PROGESTATIONAL STEROID
2
ACTION AND CLINICAL PHARMACOLOGY
GEN-MEDROXY
(medroxyprogesterone acetate), an orally-active progestational
steroid, when
administered to women with adequate endogenous estrogen, transforms a
proliferative endometrium
into a secretory endometrium.
GEN-MEDROXY
inhibits the secretion of pituitary gonadotropin
which, in turn, prevents follicular maturation and ovulation.
It has been well established that endometrial hyperplasia experienced
by a large number of post-
menopausal women receiving estrogen only therapy is caused primarily
by the action of estrogen
on the uterus in the absence of progesterone. This unchecked growth of
the endometrium
significantly increases the risk among those women with an intact
uterus of developing endometrial
cancer.
Therefore, for women with intact uteri, progestin therapy is added to
e